• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

byBryan SunandMinjee Kim
October 31, 2023
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read this study in NEJM.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

#VisualAbstract: Remibrutinib Relieves Itching and Hives in Chronic Spontaneous Urticaria

Nemolizumab Therapy for Moderate-to-Severe Prurigo Nodularis

#VisualAbstract: Nemolizumab for pruritis in atopic dermatitis patients

Tags: IL-13a antagonistnemolizumabPrurigo Nodularisprurigo nodularis treatmentpruritis
Previous Post

The Scan by 2 Minute Medicine®: Performance-Enhancing Problems, Pride Tape Bans, a Bedbug Outbreak, and Picking up on Parkinson’s  

Next Post

Extracorporeal membrane oxygenation increases bleeding risk in patients with cardiogenic shock

RelatedReports

#VisualAbstract: Remibrutinib Relieves Itching and Hives in Chronic Spontaneous Urticaria
StudyGraphics

#VisualAbstract: Remibrutinib Relieves Itching and Hives in Chronic Spontaneous Urticaria

March 19, 2025
Age and number of islet autoantibodies associated with diabetes risk
Dermatology

Nemolizumab Therapy for Moderate-to-Severe Prurigo Nodularis

August 18, 2023
#VisualAbstract: Serum antibody testing for SARS-CoV-2
StudyGraphics

#VisualAbstract: Nemolizumab for pruritis in atopic dermatitis patients

August 14, 2020
Eczema more prevalent among older adults than previously thought
Chronic Disease

Nemolizumab effective in reducing pruritis in atopic dermatitis

July 9, 2020
Next Post
Reinnervation of cardiac infarcts decreases subsequent arrhythmia incidence [PreClinical]

Extracorporeal membrane oxygenation increases bleeding risk in patients with cardiogenic shock

#VisualAbstract: Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia

#VisualAbstract: Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia

High incidence of cognitive impairment associated with colorectal cancer

Wellness Check: Spirituality

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
  • Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • 2 Minute Medicine Rewind June 23, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.